C6orf27.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](C6orf27#representative-mutation) in the original primar
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_C6orf27.md]]
21 19
22 20
## Warnings
23 21
C9.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_C9.md]]
19 17
20 18
21 19
CAD.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](CAD#representative-mutation) in the original primary da
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_CAD.md]]
21 19
22 20
## Warnings
23 21
CADPS2.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_CADPS2.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CAMTA1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_CAMTA1.md]]
19 17
20 18
21 19
CAPN5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CAPN5.md]]
19 17
20 18
21 19
CAPN7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CAPN7.md]]
19 17
20 18
21 19
CARD11.md
... ...
@@ -20,12 +20,7 @@ The functional effect of CARD11 mutations in DLBCL was explored in the original
20 20
21 21
## Relevance tier by entity
22 22
23
-|Entity|Tier|Description |
24
-|:------:|:----:|--------------------------------------|
25
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@yanBCRTLRSignaling2012]|
26
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lenzOncogenicCARD11Mutations2008]|
27
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
28
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@wuGeneticHeterogeneityPrimary2016]|
23
+[[include:table1_CARD11.md]]
29 24
30 25
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
31 26
CARD4.md
... ...
@@ -14,9 +14,7 @@ nocite: |
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
17
+[[include:table1_CARD4.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CASP8.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017]|
18
+[[include:table1_CASP8.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
CBFA2T3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]|
16
+[[include:table1_CBFA2T3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CBLB.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_CBLB.md]]
20 18
21 19
## Warnings
22 20
CBX3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CBX3.md]]
19 17
20 18
21 19
CCDC132.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CCDC132.md]]
19 17
20 18
21 19
CCDC46.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CCDC46.md]]
19 17
20 18
21 19
CCDC97.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CCDC97.md]]
19 17
20 18
21 19
CCL4.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
14
+[[include:table1_CCL4.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CCND1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@beaLandscapeSomaticMutations2013]|
13
+[[include:table1_CCND1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
CCNF.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@abateDistinctViralMutational2015]|
13
+[[include:table1_CCNF.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
CCT6B.md
... ...
@@ -16,9 +16,7 @@ Due to [minimal support](CCT6B#representative-mutations) in the original primary
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
19
+[[include:table1_CCT6B.md]]
22 20
23 21
## Warnings
24 22
CD22.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_CD22.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CD274.md
... ...
@@ -14,9 +14,7 @@ Although rare, mutations have the potential to impact PD-L1 expression and could
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011]|
17
+[[include:table1_CD274.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CD36.md
... ...
@@ -14,9 +14,7 @@ CD36 is a transmembrane glycoprotein involved in fatty acid metabolism, glucose
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@pasqualucciAnalysisCodingGenome2011]|
17
+[[include:table1_CD36.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CD44.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
14
+[[include:table1_CD44.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CD58.md
... ...
@@ -19,10 +19,7 @@ This is often accompanied by mutations in the β2-Microglobulin gene, which furt
19 19
20 20
## Relevance tier by entity
21 21
22
-|Entity|Tier|Description |
23
-|:------:|:----:|--------------------------------------|
24
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@schneiderAlterationsCD58Gene2015]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
22
+[[include:table1_CD58.md]]
26 23
27 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 25
CD70.md
... ...
@@ -18,10 +18,7 @@ In mouse models, CD70 loss promoted lymphomagenesis, consistent with its role as
18 18
19 19
## Relevance tier by entity
20 20
21
-|Entity|Tier|Description |
22
-|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
24
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
21
+[[include:table1_CD70.md]]
25 22
26 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
27 24
CD74.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_CD74.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
CD79A.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
17
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
14
+[[include:table1_CD79A.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
CD79B.md
... ...
@@ -20,11 +20,7 @@ This and other common mutations primarily occur in the immunoreceptor tyrosine-b
20 20
21 21
## Relevance tier by entity
22 22
23
-|Entity|Tier|Description |
24
-|:------:|:----:|--------------------------------------|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene with functional evidence[@davisChronicActiveBcellreceptor2010;@morinFrequentMutationHistonemodifying2011]|
26
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
27
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
23
+[[include:table1_CD79B.md]]
28 24
29 25
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 26
CD83.md
... ...
@@ -19,12 +19,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al[@mor
19 19
20 20
## Relevance tier by entity
21 21
22
-|Entity|Tier|Description |
23
-|:------:|:----:|--------------------------------------|
24
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @schmitzGeneticsPathogenesisDiffuse2018; @reddyGeneticFunctionalDrivers2017]|
26
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene [@russler-germainMutationsAssociatedProgression2023]|
27
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
22
+[[include:table1_CD83.md]]
28 23
29 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 25
CD9B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@vandenbrandRecurrentMutationsGenes2017]|
16
+[[include:table1_CD9B.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CDC123.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CDC123.md]]
19 17
20 18
21 19
CDC27.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png)|2|relevance in BL not firmly established[@maSubtypespecificCooccurringGenetic2022]|
16
+[[include:table1_CDC27.md]]
19 17
20 18
21 19
CDC42BPB.md
... ...
@@ -14,10 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
20
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established|
17
+[[include:table1_CDC42BPB.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
CDC73.md
... ...
@@ -14,10 +14,7 @@ Mutations in this gene were first described in BL in 2012 by Love et al[@loveGen
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established [@loveGeneticLandscapeMutations2012]|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_CDC73.md]]
21 18
22 19
## Warnings
23 20
CDH1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CDH1.md]]
19 17
20 18
21 19
CDH10.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CDH10.md]]
19 17
20 18
21 19
CDH17.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](CDH17#representative-mutations) in the original primary
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_CDH17.md]]
21 19
22 20
## Warnings
23 21
CDH2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
16
+[[include:table1_CDH2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CDH5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|
16
+[[include:table1_CDH5.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CDH7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CDH7.md]]
19 17
20 18
21 19
CDH8.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_CDH8.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CDH9.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
14
+[[include:table1_CDH9.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CDK3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CDK3.md]]
19 17
20 18
21 19
CDKN1A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CDKN1A.md]]
19 17
20 18
21 19
CDKN2A.md
... ...
@@ -13,12 +13,7 @@ Although CDKN2A aberrations are common in DLBCL, this gene is predominantly affe
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
19
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013]|
21
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@grandeGenomewideDiscoverySomatic2019]|
16
+[[include:table1_CDKN2A.md]]
22 17
23 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 19
CDKN2C.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@thomasGeneticSubgroupsInform2023]|
13
+[[include:table1_CDKN2C.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
CECR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CECR1.md]]
19 17
20 18
21 19
CELSR2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CELSR2.md]]
19 17
20 18
21 19
CEP164.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@albuquerqueEnhancingKnowledgeDiscovery2017]|
16
+[[include:table1_CEP164.md]]
19 17
20 18
21 19
CGN.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CGN.md]]
19 17
20 18
21 19
CHD1.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_CHD1.md]]
20 18
21 19
## Warnings
22 20
CHD3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CHD3.md]]
19 17
20 18
21 19
CHD4.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_CHD4.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
CHEK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CHEK2.md]]
19 17
20 18
21 19
CHMP4C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_CHMP4C.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CHRM5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CHRM5.md]]
19 17
20 18
21 19
CHST2.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_CHST2.md]]
20 18
21 19
## Warnings
22 20
CIC.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CIC.md]]
19 17
20 18
21 19
CIITA.md
... ...
@@ -13,10 +13,7 @@ CIITA encodes the major histocompatibility complex (MHC) class II transactivator
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokGenomicAlterationsCIITA2015]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011]|
16
+[[include:table1_CIITA.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
CILP.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
14
+[[include:table1_CILP.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CISH.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_CISH.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CLGN.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_CLGN.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CNBP.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_CNBP.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CNGA4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CNGA4.md]]
19 17
20 18
21 19
CNKSR2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_CNKSR2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CNOT2.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_CNOT2.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CNOT6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CNOT6.md]]
19 17
20 18
21 19
CNP.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CNP.md]]
19 17
20 18
21 19
CNTN6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CNTN6.md]]
19 17
20 18
21 19
CNTNAP5.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al.[@mo
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
17
+[[include:table1_CNTNAP5.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
COL11A1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_COL11A1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
COL12A1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_COL12A1.md]]
19 17
20 18
21 19
COL16A1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_COL16A1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
COL4A2.md
... ...
@@ -17,9 +17,7 @@ Due to [minimal support](COL4A2#representative-mutations) in the original primar
17 17
18 18
## Relevance tier by entity
19 19
20
-|Entity|Tier|Description |
21
-|:------:|:----:|--------------------------------------|
22
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
20
+[[include:table1_COL4A2.md]]
23 21
24 22
## Warnings
25 23
COL5A2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_COL5A2.md]]
19 17
20 18
21 19
COQ7.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
14
+[[include:table1_COQ7.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CORO2A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CORO2A.md]]
19 17
20 18
21 19
CORO7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CORO7.md]]
19 17
20 18
21 19
CPNE8.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_CPNE8.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
CPS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_CPS1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CPXM2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
14
+[[include:table1_CPXM2.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CRELD2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CRELD2.md]]
19 17
20 18
21 19
CRIP1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
14
+[[include:table1_CRIP1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CRTC3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CRTC3.md]]
19 17
20 18
21 19
CRYBG3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_CRYBG3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CSF2RB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
16
+[[include:table1_CSF2RB.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
CSNK1A1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CSNK1A1.md]]
19 17
20 18
21 19
CSNK2A1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CSNK2A1.md]]
19 17
20 18
21 19
CST7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CST7.md]]
19 17
20 18
21 19
CTCF.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
14
+[[include:table1_CTCF.md]]
17 15
18 16
## Warnings
19 17
CTNNA2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_CTNNA2.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CTNNA3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CTNNA3.md]]
19 17
20 18
21 19
CTSS.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------|
16
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@barariaCathepsinAlterationsInduce2020]|
14
+[[include:table1_CTSS.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CXCR4.md
... ...
@@ -17,12 +17,7 @@ Mutations in this gene were first described in DLBCL in 2012 [@khodabakhshiRecur
17 17
18 18
## Relevance tier by entity
19 19
20
-|Entity|Tier|Description |
21
-|:------:|:----:|--------------------------------------|
22
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@khodabakhshiRecurrentTargetsAberrant2012]|
24
-|![FL](images/icons/FL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous [@krysiakRecurrentSomaticMutations2017]|
25
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
20
+[[include:table1_CXCR4.md]]
26 21
27 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 23
CXCR5.md
... ...
@@ -14,10 +14,7 @@ CXCR5 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
17
+[[include:table1_CXCR5.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
CYB5D1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
16
+[[include:table1_CYB5D1.md]]
19 17
20 18
## Warnings
21 19
CYP24A1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CYP24A1.md]]
19 17
20 18
21 19
CYP2A6.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
14
+[[include:table1_CYP2A6.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
CYP2C18.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_CYP2C18.md]]
19 17
20 18
21 19
CYP4F22.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](CYP4F22#representative-mutation) in the original primar
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_CYP4F22.md]]
21 19
22 20
## Warnings
23 21
CYTSB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_CYTSB.md]]
19 17
20 18
21 19
CYYR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_CYYR1.md]]
19 17
20 18
21 19
DAZAP1.md
... ...
@@ -13,10 +13,7 @@ This gene has some recurrent sites of mutations (hot spots). The mutation patter
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@pararajalingamCodingNoncodingDrivers2020]|
19
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@pararajalingamCodingNoncodingDrivers2020]|
16
+[[include:table1_DAZAP1.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
DCAF6.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
17
+[[include:table1_DCAF6.md]]
20 18
21 19
## Warnings
22 20
DCHS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_DCHS1.md]]
19 17
20 18
21 19
DCP1B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_DCP1B.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DDB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DDB1.md]]
19 17
20 18
21 19
DDX10.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |Relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
14
+[[include:table1_DDX10.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
DGCR8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_DGCR8.md]]
19 17
20 18
21 19
DGKB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
+[[include:table1_DGKB.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DHCR7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png)|2|relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
16
+[[include:table1_DHCR7.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DHDH.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_DHDH.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
DHX15.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_DHX15.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
DHX16.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_DHX16.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
DHX33.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_DHX33.md]]
19 17
20 18
21 19
DIAPH2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_DIAPH2.md]]
19 17
20 18
21 19
DIAPH3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DIAPH3.md]]
19 17
20 18
21 19
DICER1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_DICER1.md]]
16 14
17 15
<<Warn("The variants reported in this gene in DLBCL failed QC")>>
18 16
DIP2B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DIP2B.md]]
19 17
20 18
21 19
DLC1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_DLC1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
DLGAP1.md
... ...
@@ -14,9 +14,7 @@ Due to [minimal support](DLGAP1#representative-mutation) in the original primary
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
17
+[[include:table1_DLGAP1.md]]
20 18
21 19
## Warnings
22 20
DLGAP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_DLGAP2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DMD.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_DMD.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DMXL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DMXL1.md]]
19 17
20 18
21 19
DNAH12.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wienandGenomicAnalysesFlowsorted2019]|
16
+[[include:table1_DNAH12.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNAH5.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_DNAH5.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
DNAH7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_DNAH7.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNAI1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_DNAI1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNAJC6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_DNAJC6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNM2.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_DNM2.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
DNMT1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_DNMT1.md]]
16 14
17 15
## Warnings
18 16
DNMT3A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|-----------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
16
+[[include:table1_DNMT3A.md]]
19 17
20 18
## Warnings
21 19
DNMT3B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@albuquerqueEnhancingKnowledgeDiscovery2017]|
16
+[[include:table1_DNMT3B.md]]
19 17
20 18
21 19
DOCK1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
14
+[[include:table1_DOCK1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
DOCK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DOCK2.md]]
19 17
20 18
21 19
DOCK5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_DOCK5.md]]
19 17
20 18
21 19
DOCK6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_DOCK6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DOLK.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DOLK.md]]
19 17
20 18
21 19
DPYD.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_DPYD.md]]
19 17
20 18
21 19
DSC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DSC2.md]]
19 17
20 18
21 19
DSC3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_DSC3.md]]
19 17
20 18
21 19
DSCAML1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DSCAML1.md]]
19 17
20 18
21 19
DSEL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
16
+[[include:table1_DSEL.md]]
19 17
20 18
21 19
DSG2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DSG2.md]]
19 17
20 18
21 19